Asahi Kasei has agreed to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company, for approximately €780 million ($920.8 million).

Aicuris adds three compounds that complement Asahi Kasei’s existing treatment portfolio and expand its presence in infectious diseases: Prevymis, Pritelivir and AIC468. This transaction is expected to close in the first quarter of fiscal 2026, subject to customary conditions.

The acquisition advances Asahi Kasei’s strategy to build a focused, sustainable specialty pharmaceutical platform serving immunocompromised and medically complex patient populations. Severe infectious diseases represent an area where Asahi Kasei already maintains a presence and is strategically adjacent to its established core transplant (Veloxis) and nephrology (Calliditas) subsidiaries, where infection-related complications remain a significant clinical concern.

By leveraging its established commercial infrastructure across transplant centers and nephrology providers, together with its advanced R&D capabilities, Asahi Kasei expects to accelerate the development and commercialization of Aicuris’s pipeline while enhancing operating efficiency and long-term earnings.

“This acquisition strengthens our position across interconnected therapeutic areas, including autoimmune diseases, transplantation, kidney disease, and severe infectious diseases. It enhances our pipeline and reinforces our strategy to build a leading global specialty pharmaceutical company,” stated Ken Shinomiya, Head of Asahi Kasei’s Healthcare Sector. “Given the strategic alignment of this asset and the opportunity to expand within an area where we already have an established presence, we acted in a nimble and disciplined manner to advance our long-term growth objectives.”

The portfolio also enhances Asahi Kasei’s financial profile, combining immediate royalty income from Prevymis with near-term commercial upside from pritelivir, for which approval is targeted in fiscal 2026. Together with the longer-term potential of AIC468, the acquisition delivers a layered growth profile that supports revenue durability and margin expansion over time.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.